Stranded Asset Write-down

The pharmaceutical manufacturing industry faces moderate-high market obsolescence and substitution risk, primarily driven by patent expirations and continuous innovation. Upon patent expiry, originator drugs typically experience a rapid decline, with generic versions capturing 80-90% of market share and significantly reducing prices.

• Patent Expiration: Drugs like Humira faced biosimilar competition from 2023, while Stelara is set for biosimilar entry in 2025, leading to significant sales erosion.
• Innovation Cycle: The constant development of novel therapies (e.g., gene therapies, advanced biologics) continuously displaces older treatments, necessitating substantial and ongoing R&D investment to maintain revenue streams.

Market contestability in pharmaceutical manufacturing is significantly high for novel drug development but varies across the broader sector, while exit friction remains substantial.

• Entry Barriers (Innovator Drugs): For innovator drugs, barriers include immense R&D costs (averaging $2.6 billion per drug), lengthy regulatory approval processes, and strong intellectual property protection (Tufts CSDD, 2020).
• Sub-sector Nuance: However, sub-sectors like generic or biosimilar manufacturing face comparatively lower, though still significant, entry barriers due to established regulatory pathways and reduced R&D investment (FDA, 2023).
• Exit Friction: Exit friction remains high across the industry due to highly specialized, non-fungible assets and ongoing regulatory obligations.

The pharmaceutical industry exhibits moderate-high structural resource intensity due to the demanding nature of its manufacturing processes. Production facilities require substantial continuous energy inputs for climate-controlled cleanrooms, often consuming 2-3 times more energy per square foot than typical commercial buildings, alongside significant water volumes for purification and process use. The industry also generates considerable hazardous waste, including chemical byproducts and solvents, necessitating complex and energy-intensive disposal methods.

• Energy Consumption: Cleanroom facilities can consume 2-3 times more energy per square foot than commercial buildings due to stringent environmental controls (International Energy Agency, 2017).
• Waste Generation: Pharmaceutical manufacturing processes generate various waste streams, including hazardous chemical waste and wastewater, contributing to significant treatment costs and environmental impact (European Environment Agency, 2019).

The pharmaceutical industry exhibits moderate-high resilience capital intensity due to the extensive investment required for innovation and specialized manufacturing. Developing a new drug from discovery through clinical trials to market launch costs an estimated $1 billion to $2.6 billion over 10-15 years.

• Investment: Significant capital is needed for R&D, clinical development, and construction of advanced manufacturing facilities.
• Adaptation: Shifting to new therapeutic areas or drug modalities (e.g., cell and gene therapies) often necessitates structural rebuilds or new specialized facilities, requiring substantial multi-billion dollar capital expenditure and years of development and approval processes.